Work

882TiP InnovaTV 208: New weekly dosing cohort in the phase II study of tisotumab vedotin in platinum-resistant ovarian cancer

Year: 2020

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2020.08.1021

Authors: S. Blank, H. Mahdi, O. Tehrani, S. Ghamande, S. Jain, L. Nicacio, I. Soumaoro, D.M. O'Malley

Institutions: Mount Sinai Health System, Icahn School of Medicine at Mount Sinai, Cleveland Clinic, Stanford Medicine, Stanford University, Augusta University, Seagen (United States), Genmab (United States), The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: AstraZeneca, GlaxoSmithKline, Icahn School of Medicine at Mount Sinai, Johnson and Johnson

OpenAlex ID: W3089183402

FWCI: 0.544

Cites:

Cited by: 5

Related to: 10